Toronto, Ontario--(Newsfile Corp. - January 9, 2025) - Alberto Morales, Executive Chairman and Chief Executive Officer, Andean Precious Metals Corp. ("Andean Precious Metals" or the "Company") (TSX: APM), and his team joined Dean McPherson, Head, Business Development, Global Mining, Toronto Stock Exchange (TSX), to open the market to celebrate the Company's graduation to Toronto Stock Exchange.Cannot view this video? Visit:https://www.youtube.com/watch?v=U22wnmTOqTEAndean is a growing precious metals produ ...

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Apt ...

Clinical-stage biopharmaceutical firm Aptorum (NASDAQ:APM) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what’s helping APM stock rocket higher.Per MarketWatch, Aptorum has agreed to merge with YOOV Group, which specializes in leveraging advanced AI techniques to optimize business operations. Specifically, the ...

Aptorum (NASDAQ:APM) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group.This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete. The remaining 10% will belong to current APM stockholders.To go along with this merger, Aptorum majority investor Jurchen Investment and wholly-owned subsidiary Aptorum Therapeutics Limited will take part in a split. That will see this legacy busin ...

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Aptorum’s and Y ...

Exhibit 99.1 Financial Statements Table of Contents | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 | F-2 | | Condensed Consolidated Statements of Operations and Comprehensive Loss for the six months ended June 30, 2023 and | | | 2022 (Unaudited) | F-3 | | Condensed Consolidated State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Financial Performance - Aptorum Group reported a net loss of $11.5 million in 2022, a significant decrease from a net loss of $27.1 million in 2021, primarily due to a gain on long-term investments of $5.6 million and a decrease in loss on investments in marketable securities of $7.9 million[8]. - Research and development expenses decreased to $9.2 million in 2022 from $10.9 million in 2021, attributed to reduced contracted research organization services as the company prepares for Phase 2 of its lead projects[8]. - General and administrative fees slightly decreased to $5.2 million in 2022 from $5.4 million in 2021, mainly due to reduced payroll expenses from a decrease in staff[8]. - Legal and professional fees increased to $2.9 million in 2022 from $2.6 million in 2021, due to more consulting services engaged during the year[9]. - Accumulated deficit increased from $(55,537,515) to $(65,337,075), a deterioration of approximately 17.5%[19]. Cash and Assets - As of December 31, 2022, Aptorum Group had $5.0 million in cash and restricted cash, down from $8.3 million as of December 31, 2021, primarily due to cash used in operating activities[9]. - Cash and cash equivalents decreased from $8,131,217 to $1,882,545, a decline of about 76.8%[19]. - Total current assets decreased from $12,688,300 to $7,067,802, a decline of approximately 44.8%[19]. - Total assets decreased from $21,907,243 to $20,867,371, a decline of about 4.7%[19]. Liabilities and Equity - Total liabilities increased significantly from $4,401,121 to $13,034,066, representing an increase of about 195.5%[19]. - Total equity attributable to shareholders decreased from $23,607,345 to $15,712,094, a reduction of approximately 33.5%[19]. - Accounts payable and accrued expenses rose from $4,172,565 to $6,166,807, an increase of approximately 47.8%[19]. - Non-controlling interests increased from $(6,101,223) to $(7,878,789), a change of approximately 29.1%[19]. Investments and Corporate Actions - Long-term investments increased from $4,156,907 to $9,744,958, representing an increase of about 134.0%[19]. - The company entered into a non-binding Letter of Intent to acquire 100% of URF Holding Group Limited, which may result in a reverse takeover and continued listing on Nasdaq[7]. - The company effectuated a ten-for-one share consolidation on January 23, 2023, changing the par value of Class A and Class B Ordinary Shares[5]. - The company executed a 1 for 10 reverse stock split effective January 23, 2023[20]. Clinical Development - The company completed Pre-IND discussions with the US FDA for its lead project ALS-4, targeting IND clearance for Phase II clinical trials in the United States[3]. - The End of Phase 1 meeting for SACT-1 with the US FDA was completed, with the FDA agreeing on the proposed clinical development plan for pediatric neuroblastoma treatment[4]. Commercialization - NativusWell® commenced commercialization in China through JD.com, one of the largest e-commerce platforms in the country[4].